356 related articles for article (PubMed ID: 30002412)
21. Tear production and ocular surface changes in experimental dry eye after elimination of desiccating stress.
Yoon KC; Ahn KY; Choi W; Li Z; Choi JS; Lee SH; Park SH
Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7267-73. PubMed ID: 21849424
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Topical Application of TSG-6, Cyclosporine, and Prednisolone for Treating Dry Eye.
Kim YJ; Ryu JS; Park SY; Lee HJ; Ko JH; Kim MK; Wee WR; Oh JY
Cornea; 2016 Apr; 35(4):536-42. PubMed ID: 26807900
[TBL] [Abstract][Full Text] [Related]
23. Secreted Mucins on the Ocular Surface.
Hori Y
Invest Ophthalmol Vis Sci; 2018 Nov; 59(14):DES151-DES156. PubMed ID: 30481820
[TBL] [Abstract][Full Text] [Related]
24. Immediate Effect of 3% Diquafosol Ophthalmic Solution on Tear MUC5AC Concentration and Corneal Wetting Ability in Normal and Experimental Keratoconjunctivitis Sicca Rat Models.
Choi KE; Song JS; Kang B; Eom Y; Kim HM
Curr Eye Res; 2017 May; 42(5):666-671. PubMed ID: 27791390
[TBL] [Abstract][Full Text] [Related]
25. Impact of Diquafosol Ophthalmic Solution on Tear Film and Dry Eye Symptom in Type 2 Diabetic Dry Eye: A Pilot Study.
Zhang Q; Zhang H; Qin G; Wu Y; Song Y; Yang L; Yu S; He X; Moore JE; Moutari S; Palme C; Xu L; He W; Pazo EE
J Ocul Pharmacol Ther; 2022 Mar; 38(2):133-140. PubMed ID: 35049373
[No Abstract] [Full Text] [Related]
26. Effects of chondrocyte-derived extracellular matrix in a dry eye mouse model.
Kim CE; Oh HN; Lee JH; Yang JW
Mol Vis; 2015; 21():1210-23. PubMed ID: 26604661
[TBL] [Abstract][Full Text] [Related]
27. The Efficiency of Cyclosporine A-Eluting Contact Lenses for the Treatment of Dry Eye.
Choi JH; Li Y; Jin R; Shrestha T; Choi JS; Lee WJ; Moon MJ; Ju HT; Choi W; Yoon KC
Curr Eye Res; 2019 May; 44(5):486-496. PubMed ID: 30580651
[TBL] [Abstract][Full Text] [Related]
28. Cyclosporine inhibits apoptosis in experimental murine xerophthalamia conjunctival epithelium.
Sun J; Wang J
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(4):469-71. PubMed ID: 17120751
[TBL] [Abstract][Full Text] [Related]
29. Calcineurin Inhibitor Voclosporin Preserves Corneal Barrier and Conjunctival Goblet Cells in Experimental Dry Eye.
Alam J; de Souza RG; Yu Z; Stern ME; de Paiva CS; Pflugfelder SC
J Ocul Pharmacol Ther; 2020 Nov; 36(9):679-685. PubMed ID: 32721249
[No Abstract] [Full Text] [Related]
30. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial.
Matsumoto Y; Ohashi Y; Watanabe H; Tsubota K;
Ophthalmology; 2012 Oct; 119(10):1954-60. PubMed ID: 22739038
[TBL] [Abstract][Full Text] [Related]
31. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome.
Demiryay E; Yaylali V; Cetin EN; Yildirim C
Eye Contact Lens; 2011 Sep; 37(5):312-5. PubMed ID: 21792057
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Topical Cyclosporine and Diquafosol Treatment in Dry Eye.
Yang JM; Choi W; Kim N; Yoon KC
Optom Vis Sci; 2015 Sep; 92(9):e296-302. PubMed ID: 26107023
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic Efficacy of Nanocomplex of Poly(Ethylene Glycol) and Catechin for Dry Eye Disease in a Mouse Model.
Lee H; Shim W; Kim CE; Choi SY; Lee H; Yang J
Invest Ophthalmol Vis Sci; 2017 Mar; 58(3):1682-1691. PubMed ID: 28319642
[TBL] [Abstract][Full Text] [Related]
34. [The protection of hydrogen-rich saline on a rat dry eye model induced by scopolamine hydrobromide].
Chu YY; Hua N; Ru YS; Zhao SZ
Zhonghua Yan Ke Za Zhi; 2017 May; 53(5):363-372. PubMed ID: 28494565
[No Abstract] [Full Text] [Related]
35. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.
Sosne G; Dunn SP; Kim C
Cornea; 2015 May; 34(5):491-6. PubMed ID: 25826322
[TBL] [Abstract][Full Text] [Related]
36. Effects of DA-6034 on aqueous tear fluid secretion and conjunctival goblet cell proliferation.
Choi SM; Lee YG; Seo MJ; Kang KK; Ahn BO; Yoo M
J Ocul Pharmacol Ther; 2009 Jun; 25(3):209-14. PubMed ID: 19456255
[TBL] [Abstract][Full Text] [Related]
37. Effects of diquafosol sodium eye drops on tear film stability in short BUT type of dry eye.
Shimazaki-Den S; Iseda H; Dogru M; Shimazaki J
Cornea; 2013 Aug; 32(8):1120-5. PubMed ID: 23635860
[TBL] [Abstract][Full Text] [Related]
38. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
[TBL] [Abstract][Full Text] [Related]
39. FTY720 ameliorates Dry Eye Disease in NOD mice: Involvement of leukocytes inhibition and goblet cells regeneration in ocular surface tissue.
Xiao W; Xu GT; Zhang J; Zhang J; Zhang Y; Ye W
Exp Eye Res; 2015 Sep; 138():145-52. PubMed ID: 26187517
[TBL] [Abstract][Full Text] [Related]
40. The effects of 3% diquafosol sodium eye drop application on meibomian gland and ocular surface alterations in the Cu, Zn-superoxide dismutase-1 (Sod1) knockout mice.
Ikeda K; Simsek C; Kojima T; Higa K; Kawashima M; Dogru M; Shimizu T; Tsubota K; Shimazaki J
Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):739-750. PubMed ID: 29484560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
